Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06243666 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Active, Not Recruitingv3
  2. Start date: Feb 15, 2024 to Feb 20, 2024
    • Eligibility criteria shortened, about 22 words
    • Study description expanded, about 8 words
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective of this study is to evaluate the protective efficacy against future infections of HPV types 16/18 or related diseases and immuno-persistence (type specific IgG antibody) of the bivalent HPV vaccine in young female populations aged 9-17 years.
Trial Details
NCT Number NCT06243666
Lead Sponsor Xiamen University
Collaborators: Xiamen Innovax Biotech Co., Ltd, Center for Disease Control and Prevention, Sheyang County, Yancheng City, Jiangsu Province, China
Conditions
(from sponsor)		 Cervical Intraepithelial Neoplasia, Cervical Cancer, Persistent Infection
Related terms Persistent Infection, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms
Enrollment 2,188 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov